Prostate Cancer in Older Adults

  • Christopher Warlick
  • Christopher Weight
  • Badrinath KonetyEmail author


The definition of the “geriatric” population is somewhat variable. For the purposes of this chapter, we will define it as those aged 70 years and older. Management of prostate cancer in this population can be particularly challenging due to two inherent yet seemingly contradictory truths. Age is a risk factor for the diagnosis of prostate cancer and also for the presence of higher risk disease. However, older men with prostate cancer are at higher risk of dying from competing causes than younger men with comparable disease. Therefore, it is imperative to recognize this reality and individualize care to each particular man with age and comorbidities in mind to try to minimize both overtreatment and undertreatment of geriatric patients with prostate cancer.


Prostate Cancer Erectile Dysfunction Radical Prostatectomy Metastatic Prostate Cancer Watchful Waiting 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Howlader NNA, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975–2009 (vintage 2009 populations). Bethesda, MD: National Cancer Institute; 2012.Google Scholar
  3. 3.
    Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095–101.PubMedCrossRefGoogle Scholar
  4. 4.
    Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708–17.PubMedCrossRefGoogle Scholar
  6. 6.
    Andriole GL, Grubb III RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–9.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Moyer VA, Force USPST. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Force USPST. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:185–91.CrossRefGoogle Scholar
  10. 10.
    Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, de Koning HJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95:868–78.PubMedCrossRefGoogle Scholar
  11. 11.
    Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006;296:2336–42.PubMedCrossRefGoogle Scholar
  12. 12.
    Hoffman RM, Barry MJ, Stanford JL, Hamilton AS, Hunt WC, Collins MM. Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study. Am J Med. 2006;119:418–25.PubMedCrossRefGoogle Scholar
  13. 13.
    Singh J, Trabulsi EJ, Gomella LG. The quality-of-life impact of prostate cancer treatments. Curr Urol Rep. 2010;11:139–46.PubMedCrossRefGoogle Scholar
  14. 14.
    Porter CR, Kodama K, Gibbons RP, Correa Jr R, Chun FK, Perrotte P, Karakiewicz PI. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol. 2006;176:569–74.PubMedCrossRefGoogle Scholar
  15. 15.
    Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982;128:492–7.PubMedGoogle Scholar
  16. 16.
    Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate. 1983;4:473–85.PubMedCrossRefGoogle Scholar
  17. 17.
    Lepor H, Gregerman M, Crosby R, Mostofi FK, Walsh PC. Precise localization of the autonomic nerves from the pelvic plexus to the corpora cavernosa: a detailed anatomical study of the adult male pelvis. J Urol. 1985;133:207–12.PubMedGoogle Scholar
  18. 18.
    Ou YC, Yang CK, Wang J, Hung SW, Cheng CL, Tewari AK, Patel VR. The trifecta outcome in 300 consecutive cases of robotic-assisted laparoscopic radical prostatectomy according to D’Amico risk criteria. Eur J Surg Oncol. 2013;39:107–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Thompson RH, Slezak JM, Webster WS, Lieber MM. Radical prostatectomy for octogenarians: how old is too old? Urology. 2006;68:1042–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Pierorazio PM, Humphreys E, Walsh PC, Partin AW, Han M. Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians. BJU Int. 2010;106:791–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Poulakis V, Witzsch U, de Vries R, Dillenburg W, Becht E. Laparoscopic radical prostatectomy in men older than 70 years of age with localized prostate cancer: comparison of morbidity, reconvalescence, and short-term clinical outcomes between younger and older men. Eur Urol. 2007;51:1341–8. discussion 1349.PubMedCrossRefGoogle Scholar
  22. 22.
    Shikanov S, Desai V, Razmaria A, Zagaja GP, Shalhav AL. Robotic radical prostatectomy for elderly patients: probability of achieving continence and potency 1 year after surgery. J Urol. 2010;183:1803–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, Graefen M, Guazzoni G, Menon M, Mottrie A, Patel VR, et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol. 2012;62:418–30.PubMedCrossRefGoogle Scholar
  24. 24.
    Mohammed N, Kestin L, Ghilezan M, Krauss D, Vicini F, Brabbins D, Gustafson G, Ye H, Martinez A. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:204–12.PubMedCrossRefGoogle Scholar
  25. 25.
    Budaus L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, Wiegel T. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol. 2012;61:112–27.PubMedCrossRefGoogle Scholar
  26. 26.
    Glass AS, McAninch JW, Zaid UB, Cinman NM, Breyer BN. Urethroplasty after radiation therapy for prostate cancer. Urology. 2012;79:1402–5.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Meeks JJ, Brandes SB, Morey AF, Thom M, Mehdiratta N, Valadez C, Granieri MA, Gonzalez CM. Urethroplasty for radiotherapy induced bulbomembranous strictures: a multi-institutional experience. J Urol. 2011;185:1761–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Kurko BS, Lief JH, Allen ZA. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;62:437–47.PubMedCrossRefGoogle Scholar
  29. 29.
    van der Wielen GJ, van Putten WL, Incrocci L. Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial. Int J Radiat Oncol Biol Phys. 2007;68:479–84.PubMedCrossRefGoogle Scholar
  30. 30.
    Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011;29:2185–90.PubMedCrossRefGoogle Scholar
  31. 31.
    Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126–31.PubMedCrossRefGoogle Scholar
  32. 32.
    Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schroder FH, Roobol MJ. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int. 2012;110:1672–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203–13.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Heron M. Deaths: leading causes for 2009: national vital statistics report. Hyattsville, MD: Division of Vital Statistics National Center For Health Statistics; 2012.Google Scholar
  35. 35.
    D’Agostino Sr RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–53.PubMedCrossRefGoogle Scholar
  36. 36.
    Daskivich TJ, Chamie K, Kwan L, Labo J, Dash A, Greenfield S, Litwin MS. Comorbidity and competing risks for mortality in men with prostate cancer. Cancer. 2011;117:4642–50.PubMedCrossRefGoogle Scholar
  37. 37.
    Abdollah F, Sun M, Schmitges J, Tian Z, Jeldres C, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. Eur Urol. 2011;60:920–30.PubMedCrossRefGoogle Scholar
  38. 38.
    Abdollah F, Sun M, Schmitges J, Thuret R, Tian Z, Shariat SF, Briganti A, Jeldres C, Perrotte P, Montorsi F, et al. Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2012;84:95–103.PubMedCrossRefGoogle Scholar
  39. 39.
    Walz J, Gallina A, Saad F, Montorsi F, Perrotte P, Shariat SF, Jeldres C, Graefen M, Benard F, McCormack M, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 2007;25:3576–81.PubMedCrossRefGoogle Scholar
  40. 40.
    Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: II the effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209–23.CrossRefGoogle Scholar
  41. 41.
    Huggins C. Endocrine-induced regression of cancers: Nobel lectures: physiology or medicine 1963–1970. Amsterdam: Elsevier; 1972. p. 235–47.Google Scholar
  42. 42.
    Maatman TJ, Gupta MK, Montie JE. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate. J Urol. 1985;133:620–1.PubMedGoogle Scholar
  43. 43.
    Heidenreich A. Current approach to androgen deprivation therapy in patients with advanced prostate cancer. Eur Urol Suppl. 2010;9:776–8.CrossRefGoogle Scholar
  44. 44.
    Weight CJ, Klein EA, Jones JS. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer. 2008;112:2195–201.PubMedCrossRefGoogle Scholar
  45. 45.
    Elliott SP, Jarosek SL, Wilt TJ, Virnig BA. Reduction in physician reimbursement and use of hormone therapy in prostate cancer. J Natl Cancer Inst. 2010;102:1826–34.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Nelson JB. Hormone therapy for prostate cancer. In: Wein AJ, editor. Campbell-Walsh urology, vol. 3. Philadelphia, PA: Saunders Elsevier; 2012. p. 2934–53.CrossRefGoogle Scholar
  47. 47.
    Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides. 1999;20:1247–62.PubMedCrossRefGoogle Scholar
  48. 48.
    Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000;132:566–77.PubMedCrossRefGoogle Scholar
  49. 49.
    Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol. 2004;46:279–83. discussion 283–4.PubMedCrossRefGoogle Scholar
  50. 50.
    Bubley GJ. Is the flare phenomenon clinically significant? Urology. 2001;58:5–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Labrie F, Dupont A, Belanger A. Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc Natl Acad Sci USA. 1984;81:3861–3.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van Der Kwast T, Wiegel T, Zattoni F, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572–83.PubMedCrossRefGoogle Scholar
  53. 53.
    Decensi AU, Boccardo F, Guarneri D, Positano N, Paoletti MC, Costantini M, Martorana G, Giuliani L. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol. 1991;146:377–81.PubMedGoogle Scholar
  54. 54.
    Chang A, Yeap B, Davis T, Blum R, Hahn R, Khanna O, Fisher H, Rosenthal J, Witte R, Schinella R, et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol. 1996;14:2250–7.PubMedGoogle Scholar
  55. 55.
    Kaisary AV, Tyrrell CJ, Beacock C, Lunglmayr G, Debruyne F. A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex study group. Eur Urol. 1995;28:215–22.PubMedGoogle Scholar
  56. 56.
    Iversen P. Bicalutamide monotherapy for early stage prostate cancer: an update. J Urol. 2003;170:S48–52. discussion S52-4.PubMedCrossRefGoogle Scholar
  57. 57.
    Small EJ, Srinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer. 1995;76:1428–34.PubMedCrossRefGoogle Scholar
  58. 58.
    Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood Jr DP, Puras-Baez A. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol. 2002;167:112–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol. 2000;38:706–13.PubMedCrossRefGoogle Scholar
  60. 60.
    Klotz L, Gleave M, Goldenberg SL. Neoadjuvant hormone therapy: the Canadian trials. Mol Urol. 2000;4:233–7. discussion 239.PubMedGoogle Scholar
  61. 61.
    Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen K. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int. 2002;90:561–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Kollmeier MA, Zelefsky MJ. What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer? Nat Clin Pract Urol. 2008;5:584–5.PubMedCrossRefGoogle Scholar
  63. 63.
    Hammerer P, Madersbacher S. Landmarks in hormonal therapy for prostate cancer. BJU Int. 2012;110 Suppl 1:23–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology. 2004;64:335–40.PubMedCrossRefGoogle Scholar
  65. 65.
    Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol. 1997;157:439–44.PubMedCrossRefGoogle Scholar
  66. 66.
    Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25:1038–42.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Smith MR, Egerdie B, Toriz NH, Feldman R, Tammela TLJ, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745–55.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Smith MR, Fallon MA, Goode MJ. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology. 2003;61:127–31.PubMedCrossRefGoogle Scholar
  69. 69.
    Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol. 2001;19:3750–7.PubMedGoogle Scholar
  70. 70.
    Moyad MA. Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women. Urology. 2002;59:20–33.PubMedCrossRefGoogle Scholar
  71. 71.
    Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol. 2009;55:62–75.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Jamadar RJ, Winters MJ, Maki PM. Cognitive changes associated with ADT: a review of the literature. Asian J Androl. 2012;14:232–8.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Dawson LA, Chow E, Morton G. Fulminant hepatic failure associated with bicalutamide. Urology. 1997;49:283–4.PubMedCrossRefGoogle Scholar
  74. 74.
    Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson Jr IM, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036–42.PubMedCrossRefGoogle Scholar
  75. 75.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.PubMedCrossRefGoogle Scholar
  76. 76.
    de Bono JS, Oudard S, Ozguroglu M. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.PubMedCrossRefGoogle Scholar
  77. 77.
    de Bono JS, Logothetis CJ, Molina A. Improved survival from metastatic prostate cancer with abiraterone acetate. N Engl J Med. 2011;364:1995–2005.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.PubMedCrossRefGoogle Scholar
  79. 79.
    Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.PubMedCrossRefGoogle Scholar
  80. 80.
    Fizazi K, Carducci M, Smith M. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized double-blind study. Lancet. 2011;377:813–22.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Christopher Warlick
    • 1
  • Christopher Weight
    • 1
  • Badrinath Konety
    • 2
    Email author
  1. 1.Department of UrologyUniversity of MinnesotaMinneapolisUSA
  2. 2.Department of UrologyUniversity of MinnesotaMinneapolisUSA

Personalised recommendations